腎細胞がん市場 - KOLの考察

当レポートでは、腎細胞がん市場について調査分析し、上市済みの治療法とパイプライン治療法の将来性に対するKOLの考察を提供しています。

目次

エグゼクティブサマリー

腎細胞がんの将来の治療パラダイム

調査目的

免疫療法

• 上市済みの治療法
  • Opdivo (nivolumab; Bristol Myers Squibb)
  • Keytruda (pembrolizumab; Merck & Co.)
  • Bavencio (avelumab; Merck Group/Pfizer)
  • Imfinzi (durvalumab; AstraZeneca)

VEGF阻害薬

• 上市済みの治療法
  • Cabometyx (cabozantinib; Exelixis/Ipsen)
  • Lenvima/Kisplyx (lenvatinib; Eisai/Merck & Co.)
  • Inlyta (axitinib; Pfizer)
  • Fotivda (tivozanib; AVEO Oncology)
  • Sutent (sunitinib; Pfizer)
  • Votrient (pazopanib; Pfizer)

mTOR阻害薬

• 上市済みの治療法
  • Afinitor (everolimus; Abbott)、Torisel (temsirolimus; Pfizer)

その他の作用機序

• 上市済みの治療法
  • Welireg (belzutifan; Merck & Co.)
• パイプライン治療法
  • Abexinostat (Xynomic Pharmaceuticals)
  • Tiragolumab (Roche)

将来の治療パラダイム

• 重要な考察のまとめ
  • KOLは、RCCに対する治癒率の向上、耐性の軽減、副作用の管理、革新的な治療法の開発が緊急に必要であることに同意しています。

付録

While acknowledging the efficacy of Merck & Co's Keytruda + Eisai's Lenvima combination what are the concerns that are muting KOLs' enthusiasm? Why do experts expect increased use of Lenvima in first-line treatment and how do they assess the value of Lenvima + Novartis' Afinitor? KOLs say Merck & Co's Welireg is an exciting development - why? KOLs critically assess the prospects of launched and pipeline therapies.

Table of Contents

Executive summary (11)

Future treatment paradigm for renal cell carcinoma

Research objectives (1)

Immunotherapy (58)

• Marketed therapies (58)
  • Opdivo (nivolumab; Bristol Myers Squibb) (22)
  • Keytruda (pembrolizumab; Merck & Co.) (21)
  • Bavencio (avelumab; Merck Group/Pfizer) (8)
  • Imfinzi (durvalumab; AstraZeneca) (7)

VEGF inhibitors (46)

• Marketed therapies (46)
  • Cabometyx (cabozantinib; Exelixis/Ipsen) (11)
  • Lenvima/Kisplyx (lenvatinib; Eisai/Merck & Co.) (11)
  • Inlyta (axitinib; Pfizer) (9)
  • Fotivda (tivozanib; AVEO Oncology) (7)
  • Sutent (sunitinib; Pfizer) (5)
  • Votrient (pazopanib; Pfizer) (3)

mTOR inhibitors (5)

• Marketed therapies (5)
  • Afinitor (everolimus; Abbott) and Torisel (temsirolimus; Pfizer) (5)

Other mechanisms of action (20)

• Marketed therapies (6)
  • Welireg (belzutifan; Merck & Co.) (6)
• Pipeline therapies (14)
  • Abexinostat (Xynomic Pharmaceuticals) (6)
  • Tiragolumab (Roche) (8)

Future treatment paradigm (11)

• Key insights summary (11)
  • KOLs agree on the urgent need to improve cure rates, reduce resistance, manage side effects and develop innovative therapies for RCC (9)

Appendix (3)

• KOL details (3)
  • North American KOLs (1)
  • European KOLs (1)